High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
Vamsidhar Velcheti(Cleveland Clinic), David L. Rimm(Yale University), Mehmet H. Kocoglu(University of Maryland, Baltimore), Scott Gettinger(Yale Cancer Center), Kavita M. Dhodapkar(Emory University), Huan Cheng(Yale University), Yanhong Deng(Sun Yat-sen University), Xiaopan Yao(Dana-Farber Cancer Institute), Kurt A. Schalper(Yale University)
Cited by 48
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k